Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 6, 2009, Pages 405-420

  Chu, Franklin ^a   Smith, Neila ^b   Uchida, Takeshi ^c  

^a San Bernardino Urological Associates   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

anticholinergic; incontinence; overactive bladder; solifenacin; urgency

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BACTERIAL MENINGITIS; BLURRED VISION; BONE DISEASE; CELLULITIS; CLINICAL TRIAL; COLON OBSTRUCTION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFESTATION; KIDNEY DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NOCTURIA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY DYSFUNCTION; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; VITAL SIGN; XEROSTOMIA;

EID: 74549209504     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.11.001     Document Type: Article

References (25)

1. Epstein L.B., and Goldberg R.P. The overactive bladder and quality of life. Int J Fertil Womens Med. 50 (2005) 30-36
2. Wein A.J., and Rackley R.R. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J Urol. 175 (2006) S5-S10
3. Abrams P., Cardozo L., Fall M., et al., Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function. Urology. 61 (2003) 37-49
4. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study [published correction appears in BJU Int. 2001;88:807]. BJU Int. 87 (2001) 760-766
5. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 20 (2003) 327-336
6. Brown J.S., Vittinghoff E., Wyman J.F., et al., Study of Osteoporotic Fractures Research Group. Urinary incontinence: Does it increase risk for falls and fractures?. J Am Geriatr Soc. 48 (2000) 721-725
7. Brown J.S., McGhan W.F., and Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 6 Suppl 1 (2000) S574-S579
8. Diokno A.C. Epidemiology and psychosocial aspects of incontinence. Urol Clin North Am. 22 (1995) 481-485
9. Serels S. The wet patient: Understanding patients with overactive bladder and incontinence. Curr Med Res Opin. 20 (2004) 791-801
10. van der Vaart C.H., de Leeuw J.R., Roovers J.P., and Heintz A.P. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 90 (2002) 544-549
11. Tubaro A., and Palleschi G. Overactive bladder: Epidemiology and social impact. Curr Opin Obstet Gynecol. 17 (2005) 507-511
12. Hu T.W., Wagner T.H., Bentkover J.D., et al. Estimated economic costs of overactive bladder in the United States. Urology. 61 (2003) 1123-1128
13. Erdem M., and Chu F. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 119 Suppl 1 (2006) 29-36
14. MacDiarmid S.A. How to choose the initial drug treatment for overactive bladder. Curr Urol Rep. 8 (2007) 364-369
15. Staskin D.R., and MacDiarmid S.A. Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. Am J Med. 119 Suppl 1 (2006) 9-15
16. Abrams P., and Andersson K.E. Muscarinic receptor antagonists for overactive bladder. BJU Int. 100 (2007) 987-1006
17. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 172 (2004) 1919-1924
18. Chapple C.R., Rechberger T., Al-Shukri S., et al., YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 93 (2004) 303-310
19. VESIcare (solifenacin succinate) prescribing information. http://www.astellas.us/docs/vesicare.pdf November 2008. Accessed July 15, 2008.
20. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al., STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 48 (2005) 464-470
21. SAS/Stat User's Guide Version 6. 4th ed. (1990), SAS Institute Inc., Cary, NC 1221-1240
22. MedDRATM version 3.2. Medical Dictionary for Regulatory Activities (2000). http://www.meddramsso.com/MSSOWeb/index.htm Accessed July 15, 2008
23. Van Elteren P.H. On the combination of two-sample tests of Wilcoxon. Bull Int Stat Inst. 37 (1960) 351-361
24. Michel M.C., and de la Rosette J.J. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int. 96 Suppl 1 (2005) 37-42
25. Guidelines for Industry: Statistical Principles for Clinical Trials (E9). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998). http://www.ich.org/cache/compo/276-254-1.html Accessed July 15, 2008